AGN-241751
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | NMDA receptor modulator |
AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD).[1][2] It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018.[1][2] Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD.[3][4][5] Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel.[2][6] As of May 2018, the drug is in phase I clinical trials.[1][2]
See also[edit]
References[edit]
- ^ a b c https://adisinsight.springer.com/drugs/800031388
- ^ a b c d https://www.prnewswire.com/news-releases/allergan-exercises-option-to-acquire-compound-from-aptinyx-discovery-platform-under-ongoing-research-collaboration-300652397.html
- ^ Vazquez GH, Camino S, Tondo L, Baldessarini RJ (2017). "Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics". CNS Neurol Disord Drug Targets. 16 (8): 858–869. doi:10.2174/1871527316666170728165648. PMID 28758582.
- ^ https://adisinsight.springer.com/drugs/800031281
- ^ https://adisinsight.springer.com/drugs/800038114
- ^ http://www.pmlive.com/pharma_news/j_and_j_therapy_for_suicidal_depressives_a_breakthrough,_says_fda_1101990
External links[edit]
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |